<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589443</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00137993</org_study_id>
    <nct_id>NCT03589443</nct_id>
  </id_info>
  <brief_title>Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus</brief_title>
  <official_title>Phase I In-vivo Study of Multiplexed Heptapeptides for Detection of Neoplasia in the Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this feasibility study is to develop new technologies for improved
      detection of Barrett's neoplasia using the scanning fiber endoscope(SFE) multiplexed imaging
      system. This study will combine the use of fluorescent-labeled peptides that bind
      specifically to pre-cancerous mucosa in the esophagus for use as novel imaging agents to
      guide endoscopic biopsy or endoscopic mucosal resection (EMR). This Phase 1 study will be
      used to provide early evidence of efficacy for the topical application of a panel of two
      peptides that bind to molecular targets that are specific for esophageal dysplasia. A panel
      is needed because cancer in the esophagus is genetically heterogeneous. The study will look
      at peptide binding in subjects with known or suspected Barrett's esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Actual">February 4, 2019</completion_date>
  <primary_completion_date type="Actual">February 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Validate the binding of the peptides using the SFE</measure>
    <time_frame>1 year</time_frame>
    <description>The binding of the fluorescent-labeled peptides (QRH-882260 and KSP-910638G) that bind to EGFR and HER2 using an SFE molecular imaging system (SFE) determined using the tumor-to-background ratio for fluorescence intensities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of the SFE to detect QRH and KSP via signal to noise ratio (SNR)</measure>
    <time_frame>1 year</time_frame>
    <description>One aspect of feasibility will be shown by examining the SNR of the images collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of the SFE to detect QRH and KSP via tumor-to-background ratio</measure>
    <time_frame>1 year</time_frame>
    <description>One aspect of feasibility will be shown by examining the tumor-to-background ratio of the images collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of the SFE to detect QRH and KSP via contrast</measure>
    <time_frame>1 year</time_frame>
    <description>One aspect of feasibility will be shown by examining the contrast in the two channels in the images collected.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>Multiplexed heptapeptides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QRH &amp; KSP sprayed onto area of interest and imaged before and after application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiplexed heptapeptides</intervention_name>
    <description>Heptapeptides QRH and KSP</description>
    <arm_group_label>Multiplexed heptapeptides</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known or suspected Barrett's esophagus

          -  Scheduled for a clinically-indicated upper endoscopy

          -  Medically cleared for the procedure

          -  Willing and able to sign informed consent

        Exclusion Criteria:

          -  Known allergy or negative reaction to the near infrared fluorophores Cy5, li-cor
             IRDye800CW, or derivatives

          -  One active chemotherapy or radiation treatment

          -  Pregnant or trying to conceive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 21, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Danielle Kim Turgeon</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

